Imugene Ltd (ASX: IMU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Imugene Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Imugene Ltd (ASX: IMU)
Latest News
Share Gainers
Why Boral, Imugene, Nickel Industries, and Sigma shares are rising today
Share Market News
3 All Ords stocks making major moves on big news today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Fallers
Why Allkem, Argosy Minerals, Audio Pixels, and Imugene shares are falling
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Why Arafura Rare Earths, Imugene, Pilbara Minerals, and Worley are charging higher
Healthcare Shares
Up 6%, guess which ASX 200 stock is the best performing so far today
Healthcare Shares
What's with the Imugene share price today?
Healthcare Shares
Why has ASX 200 healthcare stock Imugene leapt 15% in a month?
Frequently Asked Questions
-
Imugene does not pay dividends at this stage.
-
Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.
IMU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Imugene Ltd
Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.
The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.
The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu.
Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.
IMU Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
24 Apr 2024 | $0.08 | $0.00 | 0.00% | 11,486,774 | $0.08 | $0.09 | $0.08 |
23 Apr 2024 | $0.09 | $0.00 | 0.00% | 24,589,293 | $0.09 | $0.09 | $0.08 |
22 Apr 2024 | $0.09 | $0.01 | 14.08% | 46,054,531 | $0.07 | $0.09 | $0.07 |
19 Apr 2024 | $0.07 | $-0.01 | -12.82% | 66,988,213 | $0.08 | $0.08 | $0.07 |
18 Apr 2024 | $0.08 | $-0.01 | -12.05% | 32,120,149 | $0.08 | $0.09 | $0.08 |
17 Apr 2024 | $0.08 | $0.00 | 0.00% | 29,883,731 | $0.08 | $0.09 | $0.08 |
16 Apr 2024 | $0.08 | $-0.01 | -10.99% | 59,597,838 | $0.09 | $0.09 | $0.08 |
15 Apr 2024 | $0.09 | $0.00 | 0.00% | 19,603,479 | $0.09 | $0.10 | $0.09 |
12 Apr 2024 | $0.09 | $0.00 | 0.00% | 24,130,390 | $0.09 | $0.10 | $0.09 |
11 Apr 2024 | $0.10 | $-0.01 | -10.00% | 39,524,131 | $0.10 | $0.10 | $0.09 |
10 Apr 2024 | $0.10 | $0.00 | 0.00% | 29,165,724 | $0.10 | $0.11 | $0.10 |
09 Apr 2024 | $0.11 | $0.00 | 0.00% | 4,928,293 | $0.11 | $0.11 | $0.10 |
08 Apr 2024 | $0.11 | $0.00 | 0.00% | 6,428,104 | $0.11 | $0.11 | $0.10 |
05 Apr 2024 | $0.11 | $0.00 | 0.00% | 5,807,889 | $0.11 | $0.11 | $0.10 |
04 Apr 2024 | $0.11 | $0.00 | 0.00% | 20,773,074 | $0.11 | $0.11 | $0.11 |
03 Apr 2024 | $0.11 | $-0.01 | -9.09% | 4,576,469 | $0.11 | $0.11 | $0.11 |
02 Apr 2024 | $0.11 | $0.01 | 9.52% | 11,601,524 | $0.11 | $0.11 | $0.10 |
28 Mar 2024 | $0.11 | $0.00 | 0.00% | 7,120,425 | $0.11 | $0.11 | $0.10 |
27 Mar 2024 | $0.11 | $0.00 | 0.00% | 5,085,512 | $0.11 | $0.11 | $0.10 |
26 Mar 2024 | $0.11 | $0.00 | 0.00% | 4,246,240 | $0.10 | $0.11 | $0.10 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
01 Feb 2024 | Paul Hopper | Issued | 110,790,024 | $1,717,245 |
Issue of securities. Subject to release from escrow, as per announcement on 01-02-2024
|
01 Feb 2024 | Paul Hopper | Issued | 1,381,422 | $21,412 |
Issue of securities. Subject to release from escrow, as per announecment on 01-02-2024
|
01 Feb 2024 | Paul Hopper | Transfer | 10,000,000 | $1,000,000 |
As advised by the company. Transfer of shares for nil
consideration. |
12 Jan 2024 | Paul Hopper | Issued | 3,901,500 | $468,180 |
Issue of securities. 3,901,500 - Performance Rights
|
12 Jan 2024 | Lesley Russell | Issued | 1,000,000 | $120,000 |
Issue of securities. 1,000,000 - RSUs
|
12 Jan 2024 | Leslie (Mi Ok) Chong | Issued | 23,175,000 | $2,781,000 |
Issue of securities. 23,175,000 - Performance Rights
|
12 Jan 2024 | Jens Eckstein | Issued | 1,000,000 | $120,000 |
Issue of securities. 1,000,000 - RSUs
|
12 Jan 2024 | Jakob Dupont | Issued | 1,000,000 | $120,000 |
Issue of securities. 1,000,000 - RSUs
|
12 Jan 2024 | Kim Drapkin | Issued | 1,000,000 | $120,000 |
Issue of securities. 1,000,000 - RSUs
|
05 Oct 2023 | Paul Hopper | Issued | 535,714 | $24,107 |
Placement.
|
04 Oct 2023 | Leslie (Mi Ok) Chong | Issued | 535,714 | $23,571 |
Participation in share purchase plan.
|
03 Oct 2023 | Leslie (Mi Ok) Chong | Issued | 2,380,952 | $199,999 |
Placement.
|
03 Oct 2023 | Leslie (Mi Ok) Chong | Issued | 2,380,952 | $111,904 |
Placement.
|
03 Oct 2023 | Paul Hopper | Issued | 2,380,952 | $111,904 |
Placement.
|
03 Oct 2023 | Paul Hopper | Issued | 2,380,952 | $199,999 |
Placement. As per announcement on 04-10-2023
|
03 Oct 2023 | Jens Eckstein | Issued | 238,095 | $19,999 |
Placement.
|
03 Oct 2023 | Jens Eckstein | Issued | 238,095 | $11,190 |
Placement.
|
03 Oct 2023 | Lesley Russell | Issued | 238,095 | $11,190 |
Placement.
|
03 Oct 2023 | Lesley Russell | Issued | 238,095 | $19,999 |
Placement.
|
03 Oct 2023 | Kim Drapkin | Issued | 199,048 | $16,720 |
Placement.
|
03 Oct 2023 | Kim Drapkin | Issued | 199,048 | $9,355 |
Placement.
|
03 Oct 2023 | Jakob Dupont | Issued | 89,286 | $7,500 |
Placement.
|
03 Oct 2023 | Jakob Dupont | Issued | 89,286 | $4,196 |
Placement.
|
26 Sep 2023 | Paul Hopper | Issued | 535,714 | $29,999 |
Placement.
|
26 Sep 2023 | Leslie (Mi Ok) Chong | Issued | 535,714 | $29,999 |
Placement.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Ms Leslie (Mi Ok) Chong | Chief Executive OfficerManaging Director | Nov 2016 |
Ms Chong has over 23 years experience in clinical and department development in oncology. Previously, she was serving at oncology clinical development company, Genentech (a member of the Roche family), as a Senior Clinical Program Lead at the head office in San Francisco. She is also a director of Cure Brain Cancer Foundation (non-profit organisation), since April 2020.
|
Mr Paul Alex Hopper | Executive ChairmanExecutive Director | Dec 2013 |
Mr Hopper has over 20 years experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas with a focus on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. He is also a former director of Scopus BioPharma Inc.
|
Dr Lesley Russell | Non-Executive Director | Apr 2019 |
Dr Russell has over 25 years experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had new drug approvals with both Food and Drug Administration (FDA) and European Medicines Agency (EMA). Dr Russell is a director of Enanta Pharmaceuticals, since 22 November 2016 and former director of Scopus BioPharma Inc, until March 2021. Dr Russell is also a member of Risk Committee.
|
Dr Jens Eckstein | Non-Executive Director | May 2019 |
Dr Eckstein has more than 20 years venture capital experience in the biopharmaceutical industry and 10 years operational experience in drug discovery and development. He is a mentor for lifescience entrepreneurs and start-up teams in the area of innovative lifescience and healthcare information technology companies. Before joining Apollo Ventures, Dr Eckstein served as president of SR One for eight years. He is also co-founder and managing director of Action Potential Venture Capital (APVC). Previously, he was a general partner at TVM Capital. Dr Eckstein is also a member of Risk Committee.
|
Dr Jakob Dupont | Non-Executive Director | Sep 2022 |
Dr Dupont is an industry and academic drug development expert, specialising in oncology and other therapeutic areas, with more than 20 years of experience. He has made contributions to the development and approval of ten oncology drugs and has orchestrated development programs for numerous drugs. Dr Dupont is currently the Global Head of Research and Development at NASDAQ-listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversees all research and development including three clinical stage programs spanning Phase 1 through to Phase 3, and numerous pre-clinical programs. He also oversees key collaborations with academic and pharma partners, holds leadership and guidance roles for various teams within the business and acts as a spokesperson to investors and the Board of Directors. Prior to Atara, Dr Dupont spent more than six years in various roles at Genentech/Hoffman-La Roche including as Vice President, Global Head of Breast and GYN Cancer Development, in addition to a further five years at Oncomed Pharmaceuticals as Senior Vice President and Chief Medical Officer. Dr Dupont is currently an Independent Director at Apexigen (NASDAQ: APGN) and a Scientific Advisory Board Member at AMBRX (NASDAQ: AMAM). He has been published 48 times in peer-reviewed journals and has established relationships with global clinical and research oncologists, collaborative groups, industry and investors.
|
Ms Kim Drapkin | Non-Executive Director | Jun 2023 |
Ms Drapkin has 25 years of experience in the biotechnology and pharmaceutical sectors, Ms Drapkin has a background in finance, capital raising, and strategic financial planning. She held the position of CFO and Treasurer at Jounce Therapeutics, Inc. from 2015 until its acquisition in May 2023, having played a role in the companys growth and financing since its inception. Before joining Jounce, Ms Drapkin managed a financial consulting firm and served as interim CFO for various early-stage biotech companies, including Eleven Biotherapeutics, Inc., NinePoint Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer Pharmaceuticals, Avila Therapeutics, Inc., and Voyager Therapeutics, Inc. Prior to that, she held CFO positions at EPIX Pharmaceuticals and have experience at Millennium Pharmaceuticals. Ms Drapkin also currently serves as the audit committee chair and compensation committee member on Acumen Pharmaceuticals board (NASDAQ: ABOS). Previously, she served on Proteostasis Therapeutics board (NASDAQ: PTI) from 2019 to 2020 and continued on Yumanity Therapeutics board (NASDAQ: YMTX) following its merger with PTI in December 2020 until December 2022. In PTI and Yumanity, she chaired the audit committee and participated in the governance and compensation committees. Ms. Drapkin also served on transaction committees for both companies.
|
Mr Michael (Mike) Tonroe | Chief Financial OfficerCompany Secretary | Mar 2023 |
-
|
Michael (Mike) Tonroe | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
J P Morgan Nominees Australia Pty Limited | 574,331,818 | 8.94% |
Hsbc Custody Nominees (Australia) Limited | 343,635,691 | 5.35% |
Mann Family | 291,281,412 | 4.53% |
Citicorp Nominees Pty Limited | 277,068,999 | 4.31% |
Dr Nicholas Smith | 118,000,000 | 1.84% |
National Nominees Limited | 114,009,944 | 1.78% |
Bnp Paribas Noms Pty Ltd | 97,615,411 | 1.52% |
Mi Ok Chong | 77,000,000 | 1.20% |
Netwealth Investments Limited | 60,576,704 | 0.94% |
BNP Paribas Nominees Pty Ltd | 29,838,476 | 0.46% |
Ubs Nominees Pty Ltd | 26,929,629 | 0.42% |
Superhero Securities Limited | 24,386,967 | 0.38% |
Sve Capital Pty Ltd | 23,000,000 | 0.36% |
Buttonwood Nominees Pty Ltd | 21,585,740 | 0.34% |
Dr Jens Eckstein | 20,500,000 | 0.32% |
Dr Lesley Russell | 20,000,000 | 0.31% |
Mr Scott Spencer Pappin & Mrs Tracey Lee Pappin | 20,000,000 | 0.31% |
Mrs Sarah Cameron | 19,669,583 | 0.31% |
Mr James John Shaughnessy & Mrs Margaret Joy Shaughnessy | 17,798,374 | 0.28% |
Dr Nicholas Ede | 17,600,000 | 0.27% |